MetalloBio have developed a novel ruthenium platform technology with application potential as a systemic antibiotic and as a coating for medical devices.
The compounds that underpin the platform are more active than clinical antibiotics, have a novel multi-modal mechanism of action, little-no-emergence of resistance and represent a new antimicrobial class.